Rasburicase and Tumor Lysis Syndrome: Lower Dosage, Consideration of Indications, and Hyperhydration

被引：17
|
作者：
Darmon, Michael [1 ]
Guichard, Isabelle [1 ]
Vincent, Francois [2 ]
机构：
[1] St Etienne Teaching Hosp, St Etienne, France
[2] Avicenne Teaching Hosp, Bobigny, France
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2011年 / 29卷 / 03期
关键词：
SINGLE-DOSE RASBURICASE; 6; MG; ADULTS; HYPERURICEMIA; PROPHYLAXIS; MANAGEMENT; CANCER;
D O I：
10.1200/JCO.2010.32.6751
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：E67 / E68
页数：2
相关论文
共 50 条
  • [41] COST-MINIMIZATION ANALYSIS OF THE USE OF RASBURICASE IN TUMOR LYSIS SYNDROME IN PEDIATRIC ONCOLOGY
    Rodrigues, A. H.
    Follador, W.
    Abadi, M.
    Petrilli, A. S.
    VALUE IN HEALTH, 2011, 14 (03) : A166 - A166
  • [42] EFFICACY OF RASBURICASE FOR THE PROPHYLAXIS OF TUMOR LYSIS SYNDROME IN NON-HODGKIN LYMPHOMA PATIENTS
    Takahashi, Hiroyuki
    Takasaki, Hirotaka
    Ishiyama, Yasufumi
    Nakazono, Ayano
    Hattori, Yukako
    Watanabe, Reina
    Motomura, Shigeki
    Ishigatsubo, Yoshiaki
    Sakai, Rika
    ANNALS OF ONCOLOGY, 2014, 25
  • [43] Efficacy of Single Dose Rasburicase (1.5 MG) for Prophylaxis and Management of Tumor Lysis Syndrome
    Radhakrishnan, V.
    Philips, A.
    Ramamoorthy, J.
    Ganesan, P.
    Sagar, T.
    PEDIATRIC BLOOD & CANCER, 2018, 65 : S533 - S534
  • [44] Single-dose rasburicase 6 mg in the management of tumor lysis syndrome in adults
    McDonnell, AM
    Lenz, KL
    Frei-Lahr, DA
    Hayslip, J
    Hall, PD
    PHARMACOTHERAPY, 2006, 26 (06): : 806 - 812
  • [45] PREVENTION OF THE TUMOR LYSIS-ASSOCIATED HYPERURICEMIA BY RASBURICASE
    Takaiwa, N.
    Obara, N.
    Kurita, N.
    Sakata, M.
    Nishikii, H.
    Yokoyama, Y.
    Suzukawa, K.
    Hasegawa, Y.
    Chiba, S.
    ANNALS OF ONCOLOGY, 2013, 24
  • [46] FROM TUMOR LYSIS TO HEMO LYSIS: A CASE OF RASBURICASE-INDUCED METHEMOGLOBINEMIA
    Vellore, Jaasrini Reddy
    Sharma, Alisha
    Chaudary, Nauman A.
    CHEST, 2024, 166 (04) : 2369A - 2370A
  • [47] Efficacy of Single Dose Rasburicase (1.5 mg) for Prophylaxis and Management of Laboratory Tumor Lysis Syndrome
    Ashwin Philips
    Venkatraman Radhakrishnan
    Prasanth Ganesan
    T. S. Ganesan
    Jaikumar Ramamurthy
    Manikandan Dhanushkodi
    T. G. Sagar
    Indian Journal of Hematology and Blood Transfusion, 2018, 34 : 618 - 622
  • [48] A single, fixed dose of rasburicase (6 mg maximum) for treatment of tumor lysis syndrome in adults
    Giraldez, Miriam
    Puto, Katarzyna
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2010, 85 (02) : 177 - 179
  • [49] Recombinant urate oxidase (rasburicase) for the prevention and treatment of tumor lysis syndrome in patients with hematologic malignancies
    Wang, LY
    Shih, LY
    Hung, C
    Jou, ST
    Lin, KH
    Yeh, TC
    Lin, SF
    Liang, DC
    ACTA HAEMATOLOGICA, 2006, 115 (1-2) : 35 - 38
  • [50] Single-Dose Rasburicase Might Be Adequate To Overcome Tumor Lysis Syndrome In Hematological Malignancies
    Yaman, Samet
    Basci, Semih
    Turan, Gokhan
    Ulu, Bahar Uncu
    Yigenoglu, Tugce Nur
    Dal, Mehmet Sinan
    Cakar, Merih Kizil
    Altuntas, Fevzi
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 (02): : E71 - E76
12345